MedTrace Logo

AR, IGF-IR, IR and Peripheral Artery Disease

NCT04710186 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2021-01-14

No results posted yet for this study

Summary

Peripheral artery Disease (PAD) is a major cardiovascular disease that can impair quality of life (QoL). It affects more often male patients and its pathophysiology is not completely known. Probably androgen receptors and metabolism alteration may play an important role in the onset and in the progression of PAD towards its dreadful complications. The aim of this study is to evaluate the role of Androgen Recetpr , IGF-I receptor, and Insulin Receptor on the arterial wall of male patients with PAD undergoing open revascularization surgery.

Conditions

  • Androgen Receptor Abnormal
  • Insulin-Like Growth Factor I Deficiency
  • Insulin Receptor, Defect in

Interventions

PROCEDURE

arterial reconstructive open surgery

Patients with peripheral artery disease (PAD) will undergo arterial reconstructive open surgery. Samples obtained from diseased arteries of lower limbs of patients undergoing arterial reconstructive open surgery will be collected and immediately preserved at -80°. Briefly, arterial tissues were excised, homogenized using a motor driven homogenizer and total RNA was isolated using Trizol reagent (Invitrogen, Milan, Italy), in accordance with the manufacturer's instructions. The expression of Androgen Receptor (AR), insulin receptor (IR) and the IGF-I receptor (IGF-IR) will be quantified by real-time PCR using platform Quant Studio7 Flex Real-Time PCR System (Thermo Fisher Scientific, Milan, Italy), following the manufacturer's instructions.

Sponsors & Collaborators

  • University of Catanzaro

    lead OTHER

Principal Investigators

  • Raffaele Serra, M.D., Ph.D. · University Magna Graecia of Catanzaro

  • Marcello Maggiolini, M.D. · UNICAL - University of Calabria

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-01
Primary Completion
2021-02-01
Completion
2021-03-01

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04710186 on ClinicalTrials.gov